Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis

Krischan Braitsch1, Alix Schwarz1, Katrin Koch1, Mara Hubbuch1, Helge Menzel2, Ulrich Keller1,3, Katharina S. Götze1,3, Florian Bassermann1,3, Peter Herhaus1, Mareike Verbeek1

Received: 27 September 2021 / Accepted: 22 March 2022 / Published online: 1 April 2022
© The Author(s) 2022

Abstract
Reduced intensity conditioning (RIC) and reduced toxicity conditioning (RTC) regimens enable allogeneic hematopoietic stem cell transplantation (alloSCT) to more patients due to reduction in transplant-related mortality (TRM). The conditioning regimens with fludarabine and treosulfan (Flu/Treo) or fludarabine, amsacrine, cytarabine (FLAMSA)-RIC have shown their efficacy and tolerability in various malignancies. So far, no prospective study comparing the two regimens is available. Two studies compared the regimens retrospectively, in which both provided similar outcome. In this retrospective, single-center analysis, these two regimens were compared with regard to outcome, rate of acute and chronic graft versus host disease (GvHD), and engraftment. 113 consecutive patients with myeloid malignancies who received Flu/Treo or FLAMSA-RIC conditioning prior to alloSCT between 2007 and 2019 were included. Except for age, previous therapies, and remission status before alloSCT, patient characteristics were well balanced. The median follow-up time within this analysis was 44 months. There was no significant difference in absolute neutrophil count (ANC) or platelet engraftment between the two conditioning regimens. Overall survival (OS), the relapse-free survival (RFS), and the TRM were not significantly different between the two cohorts. The rate of GvHD did not differ between the two groups. In summary, this retrospective analysis shows that there is no major difference regarding tolerability and survival between the Flu/Treo and FLAMSA-RIC regimens. Despite several limitations due to uneven distribution concerning age and remission status, we demonstrate that Flu/Treo and FLAMSA-RIC provide similar outcomes and are feasible in older and intensively pre-treated patients.

Keywords Fludarabine/treosulfan · FLAMSA-RIC · Allogeneic transplantation · Conditioning regimen

Introduction
Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative treatment for hematological malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). The intensity of the conditioning regimen is known to have a significant impact on the outcome and success of transplantation and the choice of regimen in the different disease settings has been discussed and reviewed intensely in recent years [1, 2]. However, conditioning regimens are heterogeneously used and there is still a lack of knowledge in terms of direct comparison between the multiple available protocols.

Myeloablative conditioning regimens (MAC) based traditionally on total body irradiation (TBI) or busulfan may be accompanied by serious short- and long-term side
effects resulting in relatively high TRM and organ toxicity rates. As the majority of patients with AML, MDS, or MPN are older than 50 years and often present with comorbidities, reduced toxicity conditioning (RTC) or reduced intensity conditioning (RIC) regimens have been increasingly used as an alternative approach to allow curative alloSCT in patients otherwise not eligible. However, RIC regimens have shown limitations compared with conventional regimens, e.g., increased relapse and TRM rates [3–6]. Furthermore, a significant survival advantage for MAC though at the expense of expected high TRM rates has recently been demonstrated in a prospective randomized study for AML and MDS patients eligible for MAC and RIC [7]. Therefore, it remains difficult to determine the optimal conditioning protocol for each individual patient.

Other factors such as remission status prior to alloSCT, previous therapies, or disease entity, as well as individual risk profiles such as comorbidities and age, also have a crucial impact on outcome. To address these issues, various conditioning regimens, both RIC and MAC, for different patient settings have been introduced over the last years. The fludarabine, amsacrine, cytarabine-RIC (FLAMSA-RIC) regimen was initially described in 2005 as an effective and well-tolerated sequential conditioning approach for AML and MDS patients with refractory or progressive disease with an otherwise dismal prognosis [8]. Meanwhile, this regimen is well established and broadly implemented in other disease settings as well. The original combination of chemotherapy and TBI is often modified by replacing TBI with busulfan and more recently also with treosulfan, thereby further improving the tolerability [9]. Treosulfan in combination with fludarabine (Flu/Treo) was introduced in 2004 as a conditioning regimen with an excellent toxicity profile in various disease entities and has continuously gained utilization ever since [5, 10–16].

Recently, several trials have pointed towards favorable aspects of treosulfan, showing remarkable effectiveness, good feasibility, and advantages in terms of survival compared to conventional busulfan-containing conditioning regimens. Interestingly, the benefit could also be shown in elderly patients even though treosulfan-containing conditioning regimens were revealed and considered as being more of MAC than RIC character [17, 18].

As to date, no prospective studies comparing the two conditioning regimens exist. Two retrospective analyses showed no significant difference in terms of survival between the two conditioning regimens [14, 15]. While patients in the FLAMSA-RIC group had a lower risk of relapse and superior leukemia-free survival, they also had increased rates of GvHD [15]. In relapsed or refractory AML patients, no significant difference with regard to outcome could be observed [14].

We performed a retrospective analysis of patients with AML, MDS, and MPN that received either Flu/Treo or FLAMSA-RIC before alloSCT between 2007 and 2019.

**Patients and methods**

**Patients**

This retrospective analysis included 113 consecutive patients with hematologic malignancies receiving Flu/Treo or FLAMSA-RIC conditioning before alloSCT at the university hospital of the Technische Universität München between 2007 and 2019. Patient data concerning outcome, engraftment, and GvHD were analyzed retrospectively by medical chart review. All patients that received at least one dose of chemotherapy of Flu/Treo or FLAMSA-RIC conditioning were included. Missing data were accepted due to the retrospective nature of this study. Patients were eligible for alloSCT based on their underlying malignancy and institutional guidelines. All patients gave written consent according to local center guidelines.

Disease stage prior to alloSCT was defined according to the EBMT risk score [19]. Cytogenetic and molecular genetic risk was allocated in good, intermediate, and high risk. This classification was according to ELN 2017 genetic risk stratification for AML and IPSS for MDS [20, 21]. MPN were allocated to the high-risk group by absence of the bcr-abl protein or presence of the T315I mutation within the tyrosine kinase domain of bcr-abl.

HLA typing was based on high-resolution typing of MHC class I and class II. An HLA-identical related donor was defined as an 8/8 compatible donor. An HLA-identical unrelated donor was defined as 10/10 compatible. Mismatched related or unrelated donor was defined as one allele or antigen mismatch. Cord blood grafts that the one patient with dual umbilical cord blood transplantation received were 6/6 matched.

Previous therapies were extracted from medical charts and intensive chemotherapy such as induction, or consolidation therapy was distinguished from treatment with hypomethylating agents (HMA). Each applied cycle of chemotherapy was counted to reflect the cumulative amount of previous treatment. Cytoreductive therapy with hydroxyurea-bamide was not counted as a separate line of therapy.

**Conditioning regimens**

The conditioning regimen with Flu/Treo consisted of fludarabine 30 mg/m² from day – 7 to day – 3 and treosulfan 14 g/m² in patients <60 years or 12 g/m² in patients >60 years old from day – 7 to day – 5 [10]. Conditioning according to the FLAMSA-RIC protocol was conducted with a modification
to the RIC-part as previously described [8]. In the modified FLAMSA-RIC protocol, TBI was substituted by busulfan. Briefly, patients received fludarabine 30 mg/m², cytarabine 2 g/m², and amsacrine 100 mg/m² from day −12 to day −9 followed by busulfan 0.8 mg 4 times daily from day −5 to day −4 and cyclophosphamide 60 mg/kg from day −3 to day −2.

Initial immunosuppression was identical in both conditioning regimens and included a calcineurin-inhibitor (cyclosporine A (CSA) or Tacrolimus (TAC)) and mycophenolate mofetil (MMF).

**Evaluation of response**

Engraftment of WBC and platelets was defined as the first of three days with an ANC count > 0.5 × 10⁹/l and the first of seven days with an untransfused platelet count > 20 × 10⁹/l. For the grading of acute and chronic GvHD, the National Institutes of Health consensus criteria were used [22]. Fluorescence in situ hybridization (FISH) analysis for X and Y chromosomes were used for chimerism analysis in sex-mismatch transplantations. For sex-matched transplantation, the chimerism was evaluated using PCR analysis of microsatellite markers. Determination of chimerism, response, and relapse was performed on bone marrow aspirates.

**Statistical analysis**

All statistical tests were performed using GraphPad Prism (GraphPad Software). P-values < 0.05 were considered statistically significant. Comparisons of related metric measurements were performed using student’s t-test or Fisher’s exact test if used to compare quantitative data between two independent samples. Kaplan–Meier-plots were calculated using log-rank (Mantel-Cox) test.

Due to the retrospective analysis, sample size was chosen based on the number of consecutive patients treated with the selected conditioning regimens in the specified time frame.

**Results**

**Patient and donor characteristics**

In this analysis, 113 patients who were treated with alloSCT after receiving a RTC regimen either with Flu/Treo or FLAMSA-RIC between October 2007 and July 2019 were retrospectively analyzed. Seventy-two received conditioning with Flu/Treo, and 41 received FLAMSA-RIC. Both regimens were used concurrently throughout the analyzed time frame. The median age was 61 years (range 41–71 years) in the Flu/Treo group and 55 years (range 41–74 years) in the FLAMSA-RIC group. Fifty-seven percent of patients in the Flu/Treo group were over 60, contrary to only 39% of patients in the FLAMSA-RIC group. The patient characteristics concerning disease, cytogenetic, and molecular genetic risk were well balanced between the two groups (Table 1).

Forty-four (61%) patients in the Flu/Treo group had previously received intensive induction or consolidation therapy and 19 (26%) were treated with HMA alone. In the FLAMSA-RIC group, 25 patients (61%) had received intensive chemotherapy, and 11 (27%) were treated with HMA monotherapy. In median, patients in the Flu/Treo cohort had received more cycles of chemotherapy compared to patients in the FLAMSA-RIC group (Flu/Treo n = 3 (1–7); FLAMSA-RIC n = 2 (1–6)).

**Table 1** Patient characteristics of the Flu/Treo and FLAMSA-RIC cohorts. Abbreviations: Flu/Treo: fludarabine/treosulfan; FLAMSA-RIC: fludarabine, cytarabine, amsacrine – reduced intensity conditioning; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; tAML: therapy-related AML; n.a.: not annotated; HMA: hypomethylating agents; CR: complete remission; CRi: CR with incomplete hematologic recovery

|                        | Flu/Treo | FLAMSA-RIC |
|------------------------|----------|------------|
| Number of patients     | 72       | 41         |
| Age, years             |          |            |
| Median (range)         | 61 (41–71) | 55 (41–74) |
| > 60 years             | 40 (57%) | 16 (39%)   |
| Sex                    |          |            |
| Male                   | 44 (61%) | 17 (41%)   |
| Female                 | 28 (39%) | 24 (59%)   |
| Disease                |          |            |
| De novo AML            | 27 (37%) | 16 (39%)   |
| Secondary AML          | 20 (28%) | 19 (46%)   |
| MDS                    | 18 (25%) | 3 (7%)     |
| Other (MDS/MPN; tMDS, tAML) | 7 (10%) | 3 (7%)     |
| ELN-Risk criteria for AML patients |          |            |
| Favorable risk         | 6 (12%)  | 4 (11%)    |
| Intermediate risk      | 18 (37%) | 12 (33%)   |
| Adverse risk           | 22 (45%) | 17 (47%)   |
| n.a./missing           | 3 (6%)   | 3 (8%)     |
| Previous therapies     |          |            |
| Intensive chemotherapy | 44 (61%) | 25 (61%)   |
| HMA monotherapy        | 19 (26%) | 11 (27%)   |
| Number of intensive chemotherapies | 3 (1–7) | 2 (1–6)   |
| Remission before transplantation |          |            |
| 1st CR/CRi             | 31 (43%) | 9 (22%)    |
| 2nd CR/CRi             | 6 (8%)   | 0 (0%)     |
| Partial remission      | 10 (14%) | 6 (15%)    |
| Stable disease         | 14 (20%) | 7 (17%)    |
| Relapsed               | 2 (3%)   | 4 (10%)    |
| Refractory             | 2 (3%)   | 5 (12%)    |
| Upfront                | 6 (8%)   | 3 (7%)     |
| n/a                    | 1 (1%)   | 1 (2%)     |
| Progress to HMA monotherapy | 0 (0%)  | 6 (15%)    |
FLAMSA-RIC $n = 2$ (1–6), $p = 0.01$). Thirty-one (43%) were in first complete remission (CR) or CR with incomplete hematologic recovery (CRi) in the Flu/Treo group in contrast to only 9 (22%) in the FLAMSA-RIC group. Six (8%) patients achieved a second CR before alloSCT in the Flu/Treo group, and 6 (15%) patients in the FLAMSA-RIC group had MDS and progressed to sAML during HMA treatment. More patients were either relapsed or refractory in the FLAMSA-RIC group (22%) compared to the Flu/Treo cohort (6%).

In both groups, the most frequent stem cell source was peripheral blood (PB). In the FLAMSA-RIC group all but six patients received PB-derived hematopoietic stem cells. Of the six patients in the FLAMSA-RIC cohort, 5 received cord blood (CB) grafts and 1 received combined a combined PB/bone marrow (BM) graft. In the Flu/Treo group 67 (93%) patients received PB, 4 (6%) received BM, and data was unavailable for one patient. There was no significant difference between the administered doses of CD34+ cells/kg body weight (BW) (Flu/Treo vs. FLAMSA-RIC, median range: 6.8 (1.6–12.6) vs. 7.5 (1.8–17); $p = 0.13$; Table 2).

Per institutional guidelines, there was no difference between the initial immunosuppression as all patients received calcineurin inhibitors and MMF. The proportion of patients receiving ATG was not different between the two groups (Flu/Treo vs. FLAMSA-RIC: 68 (96%), vs. 41 (100%); Table 2). Data was unavailable for two patients in the Flu/Treo group.

In both cohorts, most patients had an HLA-identical unrelated donor (Flu/Treo vs. FLAMSA-RIC: 49 (68%) vs. 28 (68%)). Two patients (3%) had mismatched unrelated donors in the Flu/Treo cohort vs. no mismatched unrelated donors in the FLAMSA-RIC group. There were slightly more HLA-identical sibling donors within the FLAMSA-RIC group (Flu/Treo vs. FLAMSA-RIC: 21 (29%) vs. 13 (32%); Table 2). The median follow-up time was 44 months among all patients.

**Engraftment**

All together 108 (96%) patients reached primary ANC engraftment (Flu/Treo vs. FLAMSA-RIC, no. of patients: 71/72 vs. 37/41) and 106 (94%) patients showed platelet engraftment (Flu/Treo vs. FLAMSA-RIC: 69/72 vs. 37/41). The ANC engraftment was achieved in median 21 (range 10–35) days after transplantation in the Flu/Treo group and in median 23 (range 12–48) in the FLAMSA-RIC group. The thrombocyte engraftment occurred in median 20 days (range 10–35) after transplantation in the Flu/Treo group and in median 20 days after transplantation in the FLAMSA-RIC group (range 9–42). There was neither a significant difference in ANC ($p = 0.28$) nor in thrombocyte ($p = 0.90$) engraftment within the two groups. Data are shown in Table 2.

**Table 2**

|                      | Flu/Treo | FLAMSA-RIC |
|----------------------|----------|------------|
| **Number of patients** | 72       | 41         |
| **Graft source**     |          |            |
| PB                   | 67 (93%) | 35 (85%)   |
| BM                   | 4 (6%)   | 0 (0%)     |
| Combined PB/BM       | 0 (0%)   | 1 (2%)     |
| Cord blood           | 0 (0%)   | 5 (12%)    |
| CD34+ cells/kg BW    | 6.8 (1.6–12.6) | 7.5 (1.8–17) |
| **Immunosuppression**|          |            |
| ATG                  | 68/70 (96%) | 41/41 (100%) |
| **Donor characteristics** |      |            |
| Donor type           |          |            |
| HLA-identical sibling| 21 (29%) | 13 (32%)   |
| HLA-identical unrelated | 49 (68%) | 28 (68%)   |
| mismatched unrelated  | 2 (3%)   | 0 (0%)     |
| CMV                  |          |            |
| High risk            | 15/71 (21%) | 6/38 (16%) |
| **Engraftment**      |          |            |
| ANC engraftment      |          |            |
| No. of patients      | 71/72 (99%) | 37/41 (90%) |
| Days, median (range) | 21 (10–35) | 23 (12–48) |
| Platelet engraftment |          |            |
| No. of patients      | 69/72 (96%) | 37/41 (95%) |
| Days, median (range) | 20 (10–35) | 20 (9–42) |

**Outcome**

There was no significant difference in median OS with 15 months in the Flu/Treo group compared to 16 months in the FLAMSA-RIC group ($p = 0.92$) (Fig. 1A). The 1-year, 2-year, and 5-year OS rates in the Flu/Treo compared to the FLAMSA-RIC groups were 56% and 55%, 45% and 41%, and 30% and 33%, respectively. At the median follow-up time of 44 months, 34% of patients were alive in Flu/Treo group compared to 33% alive in the FLAMSA-RIC group. Further, no significant difference in OS could be observed among patients aged $< 60$ years ($p = 0.92$) or aged $\geq 60$ years ($p = 0.98$) among all patients. Per institutional guidelines, the cumulative dosage of treosulfan in the Flu/Treo group was 36 g/m² for patients aged $\geq 60$ years and 42 g/m² for patients aged $< 60$ years. These different dosages had no significant impact on OS ($p = 0.55$). There was also no significant difference in OS in the Flu/Treo ($p = 0.77$) and the FLAMSA-RIC group ($p = 0.98$) for patients with AML, MDS, or MDS/MPN. Similarly, no significant differences concerning OS could be observed between patients with sAML and de novo AML in both cohorts.
The median RFS was also similar in both groups with 11 months in the Flu/Treo cohort vs. 10.5 months in the FLAMSA-RIC group \((p=0.86)\) (Fig. 1B). Age of 60 years or older (FLAMSA-RIC, \(p=0.68\); Flu/Treo, \(p=0.21\)) and type of disease (FLAMSA-RIC, \(p=0.91\); Flu/Treo, \(p=0.87\)) had no significant influence on RFS, in both groups. The TRM was 31% among all patients. In the Flu/Treo group, the TRM was 32%, and 29% in FLAMSA-RIC group with no significant difference \((p=0.45)\). Most deaths not related to relapse were caused either by uncontrolled GvHD (4 patients in the Flu/Treo group and 1 patient in the FLAMSA-RIC group) or infections (16 patients in the Flu/Treo group and 11 patients in the FLAMSA-RIC group). One patient in the Flu/Treo group died of cardiac arrest.

A total of 12 (29%) patients received donor lymphocyte infusions (DLI) in the FLAMSA-RIC group, compared to 6 (8%) patients in the Flu/Treo group. Among the 12 patients receiving FLAMSA-RIC conditioning, 5 received prophylactic DLI according to Schmidt et al. [8]. The remaining 7 patients had either hematological relapse \((n=4)\), molecular relapse \((n=1)\), or loss of donor chimerism \((n=2)\). In the Flu/Treo group, no prophylactic DLI were applied; 4 patients received DLI for hematological relapse and 2 for molecular relapse.

**GvHD**

Out of the 113 studied patients, a total of 84 (76%) developed an acute GvHD and data was unavailable for 3 patients. Rates of acute GvHD I/II were slightly higher in the FLAMSA-RIC group (54%) compared to the Flu/Treo group (40%) but no significant difference could be observed \((p=0.23)\). Respectively, acute GvHD III/IV° occurred more frequently in the Flu/Treo cohort (35%) compared to the FLAMSA-RIC group (23%) without statistical significance \((p=0.20)\) (Fig. 2A).

Thirty-seven (33%) patients developed chronic GvHD; data was unavailable for 4 patients. Occurrence of mild or moderate cGvHD did not differ significantly in patients in the Flu/Treo group (27%) compared to the FLAMSA-RIC cohort (15%) \((p=0.16)\). Rates of severe cGvHD were also observed more frequently with 15% in the Flu/Treo group vs. 5% in the FLAMSA-RIC group, however there was no significant difference either \((p=0.20)\) (Fig. 2B).

**Discussion**

AlloSCT represents a curative treatment option in patients with unfavorable MDS or MPN and primary or relapsed AML. These diseases occur with higher incidence in the older population, where regimens with a balanced toxicity and tolerability profile as compared to standard MAC regimens are often required. The RTC regimens with Flu/Treo and FLAMSA-RIC have been developed and elaborated in older patients with myeloid malignancies. In this retrospective, single-center analysis, we show that the RTC regimens with Flu/Treo and FLAMSA-RIC are feasible conditioning.
regimens for older patients and do not significantly differ concerning engraftment, outcome, or the rate of GvHD.

Compared to MAC regimens, in particular, the low rate of NRM resulted in a comparable OS rate of RIC and RTC regimens. Seminal studies on the conditioning regimen with Flu/Treo have shown a NRM rate ranging between 20 and 35% [5, 10, 12, 23]. This is similar to the NRM rate of 32% seen within the Flu/Treo group in this analysis, considering the high median age and the high number of previous treatments in our cohort. Although there is no statistical significance concerning the NRM rate between the Flu/Treo and FLAMSA-RIC group, the NRM rate of 29% of the FLAMSA-RIC group was higher compared to a NRM rate of approximately 20% reported in the literature [8, 24, 25]. The high proportion of patients with advanced disease stage, active or refractory disease, and a high median age within the FLAMSA-RIC group in our analysis might partially explain this discrepancy.

The 1-year and 2-year OS rate was 56% and 39% for the Flu/Treo and 45% and 41% for the FLAMSA-RIC group, respectively. These results compare less favorable to the seminal study on the Flu/Treo protocol from Casper et al. with an OS rate of 73% at a median follow-up of 22 months. However, patients in this study were, with a median age of 49 years, younger compared to the population in this retrospective analysis [10]. A slightly lower 2-year OS rate of 34% after conditioning with Flu/Treo was seen in a study conducted in older patients with sAML and MDS [5]. The OS rate of the FLAMSA-RIC group compares well to a 2-year OS rate of 40% in the study of Schmid et al. [8]. Sheth et. al reported a higher OS and RFS rate in their retrospective study [15]. However, patients in the Flu/Treo group were in median 57 years old compared to 61 years in our study and patients in the large cohort of Sheth et al. exclusively had AML and were in their first (86% and 79%) or second (14% and 21%) CR in both the Flu/Treo and FLAMSA-RIC group, respectively. Further, that study included less than one-third of the patients with adverse risk according to 2017 ELN criteria and 79% and 78% had de novo AML compared to 37% and 39% in our study. Another study published by Saraceni et al. compared these two conditioning regimens in patients with relapsed or refractory AML and showed an OS 37% for Flu/Treo and 34% for FLAMSA-RIC conditioning [14]. In line with the other study, patients were younger compared to our cohort with a median age of 53 years in both groups.

Patients from our study had received up to 7 (ranging from 1 to 7, in median 3 in the Flu/Treo group vs. 2 in the FLAMSA-RIC group) cycles of intensive chemotherapy. This parameter is not available in most retrospective studies. However, this might be an additional factor explaining the lower rates of OS and RFS.

The overall rate of acute GvHD in the Flu/Treo group of 76% was high compared to previously reported rates ranging from 46 to 62% [5, 10, 26]. The rate of acute GvHD in the FLAMSA-RIC cohort of 77% compared similarly to a rate between 53 and 74% described in the seminal studies [8, 9, 27, 28]. The rates of chronic GvHD of 41% in the Flu/Treo group and 20% in the FLAMSA-RIC group were not excessive compared to the aforementioned studies. Exposure to multiple lines of chemotherapy prior to alloSCT has been associated with higher rates of acute GvHD and lower GvHD- and relapse-free survival [29, 30]. This might partially explain the comparatively high rate of acute GvHD observed in the Flu/Treo group. Although the results of this analysis compare well with the literature concerning outcome and GvHD rate, and although no significant differences between the two groups concerning engraftment, outcome, or higher grade acute and chronic GvHD were observed, there are obviously several limitations. First, mainly due to the different indications of the two conditioning regimens, Flu/Treo for older patients and FLAMSA-RIC for advanced/refractory diseases, the groups are not well-balanced concerning
patient age and most importantly concerning remission prior to alloSCT. Patients within the Flu/Treo group were older with a median age of 61 years compared 55 years within the FLAMSA-RIC group. While patients within both groups (FLAMSA-RIC group (47%), Flu/Treo group (45%)) had an advanced disease stage, CR rates were higher in the FLAMSA-RIC group. Although age, disease stage, and remission status are independent risk factors for a worse outcome after alloSCT and are complementary distributed, this clearly limits the conclusions drawn from this retrospective comparison. Second, due to the retrospective analysis, data concerning exact time points of GvHD occurrence and GvHD management are limited.

While the FLAMSA-RIC protocol is a well-established regimen for patients with relapsed/refractory AML or patients with high-risk MDS, conditioning with Flu/Treo was likewise able to induce CR among patients with active myeloid malignancies [31]. Flu/Treo has as well been proven to be superior to a MAC regimen with TBI in patients with MDS [11].

This retrospective single-center analysis reflects a real-world patient population with intensive prior therapy before alloSCT and a high median patient age. In this cohort, we demonstrate comparable outcomes of the RTC regimens Flu/Treo and FLAMSA-RIC in patients with myeloid malignancies and show that both regimens are feasible. However, especially due to the aforementioned limitations, prospective randomized trials that directly compare those two conditioning regimens, especially in older patients with refractory/refractory AML, are urgently needed.

Acknowledgements We are grateful to Dagmar Wäscher for assistance with data collection. We thank the staff members at Internal Medicine III for their support. UK, KSG, and FB received support from the German Cancer Consortium (DKTK).

Author contribution KB and AP collected data. KB and PH analyzed and interpreted the data. KB, PH, and MV designed the retrospective analysis. FB, HM, UK, KSG, and KK provided critical input. PH, KB, and MV wrote the manuscript. All authors critically reviewed and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Research involving human participants The data in this study represent a retrospective analysis of standard therapies and not a prospective clinical trial performed in accordance with the ethical standards of the institutional research committee.

Informed consent Written informed consent to the clinical treatment and to data analysis was obtained prior allogeneic transplantation from all patients.

Conflict of interest PH and MV have received travel support from medac GmbH Germany. The remaining authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633. https://doi.org/10.1016/j.bbtm.2009.07.004
2. Shimon I, Nagler A (2011) Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Pract Res Clin Haematol 24(3):369–379. https://doi.org/10.1016/j.beha.2011.05.002
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756–763
4. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giral S (2004) Non-ablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3):865–872. https://doi.org/10.1182/blood-2003-11-3750
5. Kroger N, Shimon A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Rengers H, Dahlke J, Atanackovic D, Nagler A, Zander A (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37(4):339–344. https://doi.org/10.1038/sj.btt.1705259
6. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socic G, Falda M, Vindelov L, Ljungman P, Jackson G, Kroger N, Rank A, Polge E, Rocha V, Mohty M, Acute Leukaemia Working Party of the European Group for B, Marrow T (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 116(6):1599–1606. https://doi.org/10.1182/blood-2011-08-375840
7. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horowitz ME (2017) Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol 35(11):1154–1161. https://doi.org/10.1200/JCO.2016.70.7091

8. Schmid C, Schleuning M, Ledderose G, Fischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675–5687. https://doi.org/10.1200/JCO.2005.07.061

9. Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, Hallek M, Scheid C, Chemnitz JM (2017) Similar outcome after allogeneic stem cell transplantation with a modified FLASMA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Ann Hematol 96(3):479–487. https://doi.org/10.1007/s00277-016-2887-4

10. Casper J, Knauf W, Dieker W, Wolf D, Steiner B, Hammer U, Wegener R, Kleine HD, Wilhelm S, Knopp A, Hartung G, Dolen G, Freund M (2004) Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2):725–731. https://doi.org/10.1182/blood-2002-11-3615

11. Hilgendorf I, Wolff D, Gromke T, Trenschel R, Elmaagachi AH, Pichlmeyer U, Freund M, Beelen DW, Casper J (2011) Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone Marrow Transplant 46(4):502–509. https://doi.org/10.1038/bmt.2010.153

12. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kroger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeyer U, Freund M (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28(20):3344–3351. https://doi.org/10.1200/JCO.2009.23.3429

13. Beelen DW, Trenschel R, Stelljes M, Groth C, Massiti T, Remenyi P, Wagner-Drouet EM, Haaptrick B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stolzel F, Schetelig J, Junghans C, Groese-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler G, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldini A, Mico MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socie G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wolf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeyer U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M (2020) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic hematopoietic stem-cell transplantation for patients with refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol 12(1):44. https://doi.org/10.1186/s13045-019-0727-4

14. Shem-Tov N, Lapidot N, Katz M, Makhoul O, Salem M, Shagdor M, Caubet S, Ravid O, Nir Nachum J, Shalev A, Feinberg M, Amsalem A, Ben-Hur M, Shalev A, Klein-Kranz L, Minchinton AJ, Lapidot N, Leibovich S, Shem-Tov N, Lapidot N (2019) Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLASMA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol 12(1):44. https://doi.org/10.1186/s13045-019-0727-4

15. Sheth V, Labopin M, Camaani J, Volin L, Brecht A, Ganser A, Mayer J, Labussiere-Wallet H, Bittenbring J, Shouval R, Savani B, Mohy M, Nagler A (2019) Comparison of FLASMA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplant 54(4):531–539. https://doi.org/10.1038/s41409-018-0288-0

16. Wedge E, Sengelov H, Hansen JW, Andersen NS, Schjoldt I, Petersen SL, Korntli B, Gronbaek K, Friis LS (2020) Improved outcomes after allogeneic hematopoietic stem cell transplantation with fludarabine/treosulfan for patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 26(6):1091–1098. https://doi.org/10.1016/j.bbmt.2020.02.010

17. Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufi G, Socie G, Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohy M, Nagler A (2018) Intravenous Busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 24(4):751–757. https://doi.org/10.1016/j.bbmt.2017.12.776

18. Sakellari I, Mallouri D, Gavrilak H, Batises I, Kaliou M, Constantinou V, Papalexandri A, Lalayanni C, Vadikolia C, Athanasiadou A, Yannaki E, Sotiropoulos D, Smias C, Anagnostopoulou A (2017) Survival advantage and comparable toxicity in reduced-toxicity treosulfan-based versus reduced-intensity busulfan-based conditioning regimen in myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 23(3):445–451. https://doi.org/10.1016/j.bbmt.2016.11.023

19. Gratwohl A (2012) The EBMT risk score. Bone Marrow Transpl 47(6):749–756. https://doi.org/10.1038/bmt.2011.110

20. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Nae T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-73196

21. Greinix HT, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088

22. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JD, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dindoff P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schulitz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956. https://doi.org/10.1016/j.bbmt.2005.09.004

23. Shimoni A, Hardan I, Shim-Tov N, Rand A, Yerushalmi R, Nagler A (2007) Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 48(12):2352–2359. https://doi.org/10.1080/10428190701671051
24. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092–1099. https://doi.org/10.1182/blood-2005-10-4165

25. Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, Hallek M, von Bergwelt-Baildon M, Scheid C, Chemnitz JM (2016) FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission. Eur J Haematol 96(5):475–482. https://doi.org/10.1111/ejh.12615

26. Nemeczek ER, Guthrie KA, Sorror ML, Wood BL, Doncy KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17(3):341–350. https://doi.org/10.1016/j.bbmt.2010.05.007

27. Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C (2012) Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Ann Hematol 91(1):47–55. https://doi.org/10.1007/s00277-011-1253-9

28. Schmid C, Schleuning M, Tischer J, Hahn J, Baumann H, Schwerdtfeger R, Ledderose G, Lallinger C, Franke A, Cook A, Holler E, Hiddemann W, Kolb HJ (2008) Long-term survival in patients suffering from AML with a complex aberrant karyotype after early allogeneic stem cell transplantation using the FLAMSA-RIC regimen: results from a prospective phase II trial. Bone Marrow Transpl 41:S75–S75

29. Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Cho SG (2019) Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma. Ann Hematol 98(7):1743–1753. https://doi.org/10.1007/s00277-019-03714-x

30. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qaziilbash MH, Champlin RE, Couriel DR (2007) Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7):2751–2758. https://doi.org/10.1182/blood-2006-07-034348

31. Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foà R, Milpied N, Peccatori J, Polge E, Mailhol A, Mohty M, Savani BN (2017) Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 123(14):2671–2679. https://doi.org/10.1002/cncr.30646

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.